Open AccessCorrelation of circulating tumor DNA EGFR mutation levels with clinical outcomes in patients with advanced lung adenocarcinoma
Author(s) -
Xiangliang Liu,
Rilan Bai,
Xiao Chen,
Yuguang Zhao,
Xu Wang,
Kewei Ma,
Huimin Tian,
Fujun Han,
Ziling Liu,
Lei Yang,
Wei Li,
Fei Gai,
Jiuwei Cui
Publication year - 2021
Publication title -
chinese medical journal/chinese medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.537
H-Index - 63
eISSN - 2542-5641
pISSN - 0366-6999
DOI - 10.1097/cm9.0000000000001760
Subject(s) - adenocarcinoma , medicine , biomarker , concordance , oncology , lung cancer , digital polymerase chain reaction , lung , pathology , polymerase chain reaction , cancer , biology , gene , genetics
Circulating tumor DNA (ctDNA) is a promising biomarker for non-invasive epidermal growth factor receptor mutations (EGFRm) detection in lung cancer patients, but existing methods have limitations in sensitivity and availability. In this study, we used the ΔCt value (mutant cycle threshold [Ct] value-internal control Ct value) generated during the polymerase chain reaction (PCR) assay to convert super-amplification-refractory mutation system (superARMS) from a qualitative method to a semi-quantitative method named reformed-superARMS (R-superARMS), and evaluated its performance in detecting EGFRm in plasma ctDNA in patients with advanced lung adenocarcinoma.